Increased intensity of therapy for osteosarcoma in the last 30 years has improved prognosis. 70–80% of patients with non metastatic osteosarcoma can now be cured, but late side effects occur. Fertility of survivors is becoming of greater importance.

We retrospectively studied all consecutive female long term survivors of localized osteogenic sarcoma of childhood and adolescence treated at the Schneider Children‘s Medical Center of Israel. Patients were treated with 3 different protocols including the use of Methotrexate, Adriamycin, Cisplatin, Bleomycin, Cytoxan, Vincristine, Actinomycin D, Melphalan and Ifosfamide.

Sixteen female survivors of non metastatic osteogenic sarcoma were treated from 1/1977 to 12/2001, with a minimum follow up of 6.3 years (max. 29 years) from the end of therapy. Median age at diagnosis was 11.7 (range 9.0–16.8) years. Twelve out of 16 (75%) are married and have between them 31 children, mean 2.7 (range 1–7) children. Of these 11 have children and one is currently pregnant with her first child. None of the females reported difficulties in conceiving their first child. The maximum interval from marriage to first delivery was 2.5 years. Two females had 3 spontaneous abortions between the 2nd–4th pregnancies. Four out of 9 female survivors who received > 360mg/m2 of adriamycin were treated with cardiomimetic drugs and/or ACE inhibitors during pregnancy. All four had 2–4 children/ female survivor. The children of survivors are healthy with no birth defects. Mean length of pregnancy was 38.6 weeks and mean birth weight was 2865 grams. No survivors had undergone invasive fertility preservation procedure and only one unmarried patient was using GnRH analogs.

Despite reports of transient disturbances in menstruation, all married females were fertile. Our results question the need for fertility preservation using GnRH analogs or invasive procedures such as ovary or egg preservation for non metastatic osteogenic sarcoma female patients.